Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-glucosidase II (GII) is a heterodimeric enzyme located in the endoplasmic reticulum (ER) that plays a critical role in glycoprotein processing and maturation. It catalyzes the removal of two α1-3-linked glucose residues from N-linked oligosaccharides, which is essential for proper protein folding, stability, and trafficking. GII consists of a catalytic alpha subunit (GIIα) and a regulatory beta subunit (GIIβ). Inhibition of GII is being explored as a therapeutic strategy for various diseases, including viral infections, cancer, and diabetes.
Inhibition of alpha-glucosidase II disrupts N-glycan processing, affecting glycoprotein folding and function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-glucosidase II (GII).